Liquidia Corporation (LQDA)

Etorro trading 970x250
Liquidia Corporation (LQDA) Logo

About Liquidia Corporation

Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, and commercialization services for rare disease pharmaceutical products, such as generic Remodulin, a parenteral formulation of treprostinil for pulmonary arterial hypertension. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina. Address: 419 Davis Drive, Morrisville, NC, United States, 27560

Liquidia Corporation News and around…

Latest news about Liquidia Corporation (LQDA) common stock and company :

Liquidia (NASDAQ:LQDA) shareholder returns have been splendid, earning 109% in 1 year
10 Jan, 2022 Yahoo! Finance

Unless you borrow money to invest, the potential losses are limited. On the other hand, if you find a high quality...

Liquidia Re-Finances Debt Facility With Silicon Valley Bank To Increase To $40.0 Million
07 Jan, 2022 Yahoo! Finance

MORRISVILLE, N.C., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the closing of a debt facility on January 7, 2022, with Silicon Valley Bank (SVB) which provides Liquidia with up to $40.0 million in term loans of which the first $20.0 million was funded at closing. Liquidia initially entered a debt facility with SVB in March 2021 that provided up to $20.5 million in term loans of which $10.5 million had been funded to date. Under the terms of the new debt

Liquidia appoints new CEO at pivotal juncture
06 Jan, 2022 Yahoo! Finance

The new CEO previously led United Therapeutics, which is currently in the midst of a legal battle with Liquidia.

The Daily Biotech Pulse: Liquidia Jumps On New CEO Appointment, Spectrum, Aravive Secure New Funding, Allena To Explore Strategic Alternatives
04 Jan, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Liquidia Appoints Pharma ...

23 Stocks Moving in Tuesday's Pre-Market Session
04 Jan, 2022 FinancialContent

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 62.1% to $1.05 in pre-market trading as the company issued a clinical and ...

Liquidia Corporation Announces Chief Executive Officer Transition
03 Jan, 2022 Yahoo! Finance

MORRISVILLE, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Dr. Roger Jeffs has been appointed as Chief Executive Officer (CEO) effective January 3, 2022 and will continue as a director on the board. He succeeds Damian deGoa who will remain a director of the Company and will provide transition support through January 31, 2022. “Roger is a talented leader with incredible knowledge and experience in drug development and commercializing rare disease drug

United Therapeutics accuses Liquidia, former employee of misappropriating trade secrets
03 Jan, 2022 Yahoo! Finance

A pharmaceutical company with a headquarters in Research Triangle Park claims a former employee took confidential information with him to a drugmaker based in Morrisville.

Stipulation of Partial Judgment In Favor of Liquidia Filed In Hatch-Waxman Litigation
29 Dec, 2021 Yahoo! Finance

MORRISVILLE, N.C., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that United Therapeutics Corporation (UTC) has filed a stipulation of partial judgment with respect to U.S. Patent No. 9,604,901 (‘901 patent) in the on-going litigation under the Hatch-Waxman Act (Hatch-Waxman). Under the stipulation of partial judgment, UTC has agreed to the entry of judgment of Liquidia’s non-infringement of the ’901 patent based on the Court’s construction of certain term

12 Health Care Stocks Moving In Tuesday's After-Market Session
14 Dec, 2021 FinancialContent

Gainers Star Equity Hldgs (NASDAQ:STRR) shares increased by 12.15% to $2.86 during Tuesday's after-market session. Trading volume for ...

Liquidia Corporation (NASDAQ:LQDA) insiders placed bullish bets worth US$1.6m in the last 12 months
26 Nov, 2021 Yahoo! Finance

In the last year, multiple insiders have substantially increased their holdings of Liquidia Corporation ( NASDAQ:LQDA...

Land This Bargain Even Cheaper Than General Counsel Schundler Did
22 Nov, 2021 FinancialContent

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 10, Liquidia Corp's General Counsel, Russell Schundler, invested $496,834.09 into 117,908 shares of LQDA, for a cost per share of $4.21..

91 Biggest Movers From Yesterday
12 Nov, 2021 FinancialContent

Gainers NuZee, Inc. (NASDAQ: NUZE) shares jumped 164.5% to settle at $5.29 on Thursday. NuZee manufacturing partner, Cuvee Coffee, ...

Liquidia to Participate in the Jefferies London Healthcare Conference
11 Nov, 2021 Yahoo! Finance

MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer of Liquidia, will provide an update on the company's business during a fireside chat at the Jefferies 2021 Virtual London Healthcare Conference being held November 16-19, 2021 . The fireside chat will be available to registered participants on-demand beginning at 8:00 a.m. GMT on November 18, 2021. A webcast of the event will be available on th

Top Buys by Top Brass: General Counsel Schundler's $496.8K Bet on LQDA
11 Nov, 2021 FinancialContent

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

12 Health Care Stocks Moving In Thursday's Intraday Session
11 Nov, 2021 FinancialContent

Gainers Liquidia (NASDAQ:LQDA) stock increased by 17.49% to $4.97 during Thursday's regular session. Trading volume for Liquidia's ...

Notable Liquidia Insider Makes $495K Buy
11 Nov, 2021 Yahoo! Finance

Russell Schundler, Insider at Liquidia (NASDAQ:LQDA), made a large insider buy on November 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Schundler purchased 117,908 shares of Liquidia at at prices ranging from $4.18 to $4.28. The total transaction amounted to $496,834. Following the transaction, Schundler now owns 235,088 shares of the company, worth $1,123,720. Liquidia shares are trading up 13.0% at $

4 Penny Stocks Insiders Are Buying
11 Nov, 2021 FinancialContent

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

Morrisville firm gets tentative approval for hypertension treatment, but lawsuit still a hurdle
10 Nov, 2021 Yahoo! Finance

The FDA has granted tentative approval of a Morrisville-based drugmaker's treatment for pulmonary arterial hypertension, but a lawsuit is keeping the company from marketing the drug.

Liquidia's Inhaled Treprostinil Powder Scores Tentative FDA Approval For PAH
08 Nov, 2021 FinancialContent

TheFDA has granted tentative approvaltoLiquidia Corporation's(NASDAQ: LQDA) Yutrepia (treprostinil) ...

FDA Grants Tentative Approval for Liquidia’s YUTREPIA™ (Treprostinil) Inhalation Powder
08 Nov, 2021 Yahoo! Finance

First dry-powder formulation of treprostinil to meet criteria required for FDA approvalFinal FDA approval may occur in October 2022 or earlier upon resolution of on-going litigationConference call and webcast scheduled for today at 9:00 a.m. Eastern Standard Time MORRISVILLE, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder, previou

Liquidia Reaches Analyst Target Price
04 Nov, 2021 FinancialContent

In recent trading, shares of Liquidia Corp (LQDA) have crossed above the average analyst 12-month target price of $4.25, changing hands for $4.32/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..

Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates
03 Nov, 2021 Yahoo! Finance

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -16.67% and 28.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Reports Third Quarter 2021 Financial Results and Provides Corporate Update
03 Nov, 2021 Yahoo! Finance

- Increased adoption of generic Treprostinil Injection by patients, physicians and payers- Completed on-site pre-approval inspections by FDA of two U.S. manufacturing facilities- Anticipate FDA action on LIQ861 near PDUFA goal date of November 7, 2021 MORRISVILLE, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the quarter and nine-months ended September 30, 2021. Damian deGoa, Liquidia’s Chief Executi

12 Health Care Stocks Moving In Monday's Intraday Session
18 Oct, 2021 FinancialContent

Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 ...

Is Liquidia (NASDAQ:LQDA) Weighed On By Its Debt Load?
12 Oct, 2021 Yahoo! Finance

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

46 Biggest Movers From Yesterday
12 Oct, 2021 FinancialContent

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full ...

28 Stocks Moving In Monday's Mid-Day Session
11 Oct, 2021 FinancialContent

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
11 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, traders! We're kicking off the week right with a look at the biggest pre-market stock market movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

15 Stocks Moving in Monday's Pre-Market Session
11 Oct, 2021 FinancialContent

Gainers Trevi Therapeutics, Inc. (NASDAQ: TRVI) rose 32.5% to $1.59 in pre-market trading after the company filed Friday to ...

Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent
08 Oct, 2021 Yahoo! Finance

MORRISVILLE, N.C., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 9,604,901 (‘901 patent) owned by United Therapeutics Corporation (UTC) and listed in the Orange Book for Tyvaso® (treprostinil inhalation solution). In its ruling, the PTAB found that seven of the nine claims were unpatentable. Only the narrower dependent c

Liquidia Corporation (LQDA) is a NASDAQ Common Stock listed in , ,

970x250